15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Werewolf Therapeutics Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $4.00 to $7.00, a moderate spread. The average target of $5.50 sits 522% above the current $0.88. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.17 next quarter toward $-0.59 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Werewolf Therapeutics Inc.
As of Aug, 2 of 2 firms rate HOWL a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
HOWL EPS & revenue forecast
EPS · NEXT QUARTER
$-0.17
Range $-0.17 – $-0.17 · 1 analysts · +0% YoY
Next period, 1 analysts expect Werewolf Therapeutics Inc to earn $-0.17 a share (range $-0.17 – $-0.17), versus $-0.17 a year earlier. Full-year consensus is $-0.89, growing to $-0.59 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Werewolf Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HOWL.
#1
Andres Y. Maldonado
HC Wainwright & Co. · Rank #262
Buy
$4.00+352.6% to target
Overall win rate
37%
+ Follow
#2
Daina Graybosch
Leerink Partners · Rank #322
Buy
$10.00+1031.6% to target
Overall win rate
40%
+ Follow
#3
Reni J. Benjamin
JMP Securities · Rank #353
Buy
$3.00+239.5% to target
Overall win rate
33%
+ Follow
#4
Robert Driscoll
Wedbush · Rank #367
Buy
$6.00+579.0% to target
Overall win rate
30%
+ Follow
#5
Jason Zemansky
B of A Securities
Buy
$7.00+692.1% to target
Coverage
—
+ Follow
HOWL stock forecast FAQ
What is HOWL's average 12-month price target?+
The 2 analysts with a live target average $5.50 for Werewolf Therapeutics Inc over the next 12 months, ranging from a $7.00 high to a $4.00 low.
Is HOWL stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for HOWL?+
The Street-high target is $7.00 (B of A Securities), and the Street-low is $4.00 (HC Wainwright & Co.). The average of all 2 active targets is $5.50.
How many Wall Street analysts cover HOWL?+
2 analysts have an active rating on Werewolf Therapeutics Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering HOWL?+
Among analysts who currently cover HOWL, Andres Y. Maldonado of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #262). Their current call is Buy with a $4.00 target.
What is Werewolf Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.17 per share (range $-0.17 – $-0.17) across 1 analysts. Full-year EPS is projected at $-0.89, rising to $-0.59 the following year.
How much revenue is Werewolf Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading HOWL lately?+
As of Aug, 2 of 2 firms rate HOWL a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HOWL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
